A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 95-100

  Lee, S J ^a   Lee, J W ^a   Min, J A ^a   Park, C S ^a   Kim, B G ^a   Lee, J H ^a   Bae, D S ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Consolidation chemotherapy; Disease free survival; Ovarian cancer; Paclitaxel; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HISTOLOGY; HUMAN; INFECTION; INFORMED CONSENT; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PARESTHESIA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PILOT PROJECTS; PROBABILITY; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645341194     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00282.x     Document Type: Article

References (20)

1. Office of Population Censuses and Surveys. Cancer statistics: registrations 1987 England and Wales. London HMSO 1988.
2. Boyle P la Vecchia C Walker A. Volume 24 of the Annual report on the results of treatment in Gynecologic Cancer. J Epidemiol Biostat 2001 6 116.
3. Gershenson DM Mitchell MF Atkinson N et al. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: maintenance therapy reconsidered. Gynecol Oncol 1992 47 7 13.
4. Hakes TB Chalas E Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992 45 284 9.
5. Bertelson K Jakobsen A Stroyer J et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group Trial (DACOVA). Gynecol Oncol 1993 49 30 6.
6. Lambert HE Rustin GJ Gregory WM Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: a North Thames Ovary Group Study. Ann Oncol 1997 8 327 33.
7. Markman M Liu PY Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial. J Clin Oncol 2003 21 2460 5.
8. Rubin SC Hoskins WJ Saigo PE et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991 42 137 41.
9. MacGibbon A Bucci J MacLeod C et al. Whole abdominal radiation following second-look laparotomy for ovarian carcinoma. Gynecol Oncol 1999 75 62 7.
10. Perez-Gracia JL Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced setting: systemic review of the literature and implications for future research. Gynecol Oncol 2002 84 201 9.
11. Hall G Coleman R Stead M et al. Maintenance treatment with interferon for advanced ovarian cancer. Proc ASCO 2000 19 386. Abstract 1529.
12. Scarfone G Mericio C Garavaglia E et al. A phase III trial of consolidation versus nihil (nil) for advanced epithelial ovarian cancer (AEOC) after complete remission. Proc ASCO 2002 21 204. Abstract 812.
13. De Placido S Scambia G Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. J Clin Oncol 2004 22 2635 42.
14. Roed H Vindelov LL Christensen IJ Spang-Thomsen M Hansen HH. The cytotoxic activity of cisplatin, carboplatin, and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay. Eur J Cancer Clin Oncol 1998 24 247 53.
15. Canetta R Bragman K Smaldone L Rozencweig M. Carboplatin: current status and future prospects. Cancer Treat Rev 1988 15 Suppl. B 17 32.
16. Ozols RF Berhens BC Ostchega Y Young RC. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 1985 12 Suppl. A 59 65.
17. Waterhouse DM Reynolds RK Natale RB. Combined carboplatin and cisplatin. Cancer 1993 71 4060 6.
18. Rowinsky EK Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995 332 1004 14.
19. Browder T Butterfield CE Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000 60 1878 86.
20. Markman M Hakes T Barakat R et al. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center Protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 1996 14 796 9.